The vision of the 340B Drug Pricing Program is to expand access and maximize resources for enhanced care, but for pharmaceutical manufacturers, it poses significant operational and compliance challenges. As pricing frameworks intersect with Medicaid rebates, Medicare programs, and commercial payer systems, the risk of duplicate discounts, diversion, and revenue leakage continues to grow.
In this white paper, we examine how structural gaps in current processes, combined with fragmented data visibility and federal regulatory changes, are increasing compliance risk across the 340B ecosystem. We also explore how integrated, claim-level visibility and cross-program reconciliation can help manufacturers identify duplicate discounts, manage regulatory complexity, and protect revenue integrity.
Download the white paper to understand where the risks are building and what your organization needs to stay ahead of them.
